KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $0.67.

  • Royalty Pharma's EPS (Weighted Average and Diluted) fell 4462.81% to $0.67 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.76, marking a year-over-year decrease of 3098.04%. This contributed to the annual value of $2.24 for FY2024, which is 1146.17% down from last year.
  • As of Q3 2025, Royalty Pharma's EPS (Weighted Average and Diluted) stood at $0.67, which was down 4462.81% from $0.07 recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's EPS (Weighted Average and Diluted) peaked at $1.21 during Q3 2024, and registered a low of -$1.04 during Q4 2022.
  • In the last 5 years, Royalty Pharma's EPS (Weighted Average and Diluted) had a median value of $0.32 in 2022 and averaged $0.4.
  • In the last 5 years, Royalty Pharma's EPS (Weighted Average and Diluted) crashed by 90377.5% in 2022 and then soared by 540000.0% in 2025.
  • Royalty Pharma's EPS (Weighted Average and Diluted) (Quarter) stood at $0.13 in 2021, then crashed by 903.77% to -$1.04 in 2022, then soared by 205.77% to $1.1 in 2023, then tumbled by 48.84% to $0.56 in 2024, then increased by 19.05% to $0.67 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.67 in Q3 2025, compared to $0.07 in Q2 2025 and $0.55 in Q1 2025.